# A Trial to Determine the Efficacy and Safety of Presendin in IIH

> **NCT05347147** · PHASE3 · TERMINATED · sponsor: **Invex Therapeutics Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Idiopathic Intracranial Hypertension

## Interventions

- **DRUG:** Presendin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05347147
- **Lead sponsor:** Invex Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-18
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-10-20
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Following a strategic evaluation of its IIH EVOLVE Phase III clinical trial investigating Presendin™, the Invex Board has made the difficult decision that the continuation of the trial is not viable and therefore the trial has been terminated.
- **Last updated:** 2024-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05347147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05347147, "A Trial to Determine the Efficacy and Safety of Presendin in IIH". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05347147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*